Annotation Detail
Information
- Associated Genes
- UGT1A1
- Associated Variants
-
UGT1A1 UNKNOWN
UGT1A1 UGT1A1*60 - Associated Disease
- cancer
- Source Database
- CIViC Evidence
- Description
- In a phase 1 trial belinostat (400-800mg/m2/24h) was administered to 25 patients in combination with cisplatin and etoposide. Endpoints were associations between genotype of UGT1A1 and pharmacokinetics, toxicities and proteine lysine acetylation. Belinostat AUC and half-life was significantly increased in UGT1A1*60 carriers, and they were at greater risk for thrombocytopenia.
- Variant Origin
- Common Germline
- Variant Origin
- Common Germline
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1795
- Gene URL
- https://civic.genome.wustl.edu/links/genes/12422
- Variant URL
- https://civic.genome.wustl.edu/links/variants/732
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Cancer
- Evidence Direction
- Supports
- Drug
- Belinostat
- Evidence Level
- B
- Clinical Significance
- Adverse Response
- Pubmed
- 26313268
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Belinostat | Adverse Response | true |